These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 33847661)
1. A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article. Nakajo M; Kitajima K; Toriihara A; Arigami T; Daisaki H; Nakamura A; Ohtsuka T; Miwa H; Yoshiura T Medicine (Baltimore); 2021 Apr; 100(15):e25494. PubMed ID: 33847661 [TBL] [Abstract][Full Text] [Related]
3. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739 [TBL] [Abstract][Full Text] [Related]
4. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab. Skougaard K; Nielsen D; Jensen BV; Hendel HW J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497 [TBL] [Abstract][Full Text] [Related]
5. Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT. Park S; Lee Y; Kim TS; Kim SK; Han JY Medicine (Baltimore); 2020 Dec; 99(51):e23815. PubMed ID: 33371161 [TBL] [Abstract][Full Text] [Related]
7. FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST. Depardon E; Kanoun S; Humbert O; Bertaut A; Riedinger JM; Tal I; Vrigneaud JM; Lasserre M; Toubeau M; Berriolo-Riedinger A; Dygai-Cochet I; Fumoleau P; Brunotte F; Cochet A PLoS One; 2018; 13(7):e0199529. PubMed ID: 30011328 [TBL] [Abstract][Full Text] [Related]
8. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer. Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466 [TBL] [Abstract][Full Text] [Related]
9. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib. Ho KC; Fang YD; Chung HW; Liu YC; Chang JW; Hou MM; Yang CT; Cheng NM; Su TP; Yen TC Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2155-2165. PubMed ID: 27260520 [TBL] [Abstract][Full Text] [Related]
10. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma. Kitajima K; Kuribayashi K; Minami T; Yokoyama H; Nakamura A; Hashimoto M; Kijima T; Hasegawa S; Kaida H; Yamakado K Oncotarget; 2024 Jun; 15():408-417. PubMed ID: 38900646 [TBL] [Abstract][Full Text] [Related]
11. Comparison of modified Response Evaluation Criteria in Solid Tumors, European Organization for Research and Treatment of Cancer criteria, and PET Response Criteria in Solid Tumors for evaluation of tumor response to chemotherapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma. Kitajima K; Maruyama M; Minami T; Yokoi T; Kuribayashi K; Kijima T; Hashimoto M; Hasegawa S; Yamakado K Nucl Med Commun; 2020 Aug; 41(8):790-799. PubMed ID: 32516245 [TBL] [Abstract][Full Text] [Related]
12. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Tan AC; Emmett L; Lo S; Liu V; Kapoor R; Carlino MS; Guminski AD; Long GV; Menzies AM Ann Oncol; 2018 Oct; 29(10):2115-2120. PubMed ID: 30137228 [TBL] [Abstract][Full Text] [Related]
13. Comparison of prognostic value of different metabolic response criteria determined by PET/CT in patients with metastatic breast cancer under CDK 4/6 inhibitor treatment. Önner H; Eren OÖ; Körez MK; Yilmaz F; Kara Gedik G Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(5):319-324. PubMed ID: 37030597 [TBL] [Abstract][Full Text] [Related]
14. Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT. Kitajima K; Maruyama M; Yokoyama H; Minami T; Yokoi T; Nakamura A; Hashimoto M; Kondo N; Kuribayashi K; Kijima T; Hasegawa S; Yamakado K Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33806464 [TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for response evaluation in recurrent carcinoma cervix: does metabolic response predict survival? Dhull VS; Sharma P; Sharma DN; Maharjan S; Suman Kc S; Patel C; Bal C; Kumar R Int J Gynecol Cancer; 2014 Feb; 24(2):312-20. PubMed ID: 24407578 [TBL] [Abstract][Full Text] [Related]
16. The early prediction of pathological response to neoadjuvant chemotherapy and prognosis: comparison of PET Response Criteria in Solid Tumors and European Organization for Research and Treatment of Cancer criteria in breast cancer. Lian W; Liu C; Gu B; Zhang J; Lu L; Pan H; Yao Z; Wang M; Song S; Zhang Y; Yang Z Nucl Med Commun; 2020 Mar; 41(3):280-287. PubMed ID: 32032193 [TBL] [Abstract][Full Text] [Related]
17. Comparison Between Rossi G; Bauckneht M; Genova C; Rijavec E; Biello F; Mennella S; Dal Bello MG; Cittadini G; Bruzzi P; Piva R; Ceriani V; Sambuceti G; Lopci E; Morbelli S; Grossi F J Nucl Med; 2020 Jul; 61(7):990-998. PubMed ID: 31806768 [TBL] [Abstract][Full Text] [Related]
18. Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma. Amrane K; Le Goupil D; Quere G; Delcroix O; Gouva S; Schick U; Salaun PY; Abgral R; Alavi Z; Keromnes N; Querellou S Medicine (Baltimore); 2019 Jul; 98(29):e16417. PubMed ID: 31335691 [TBL] [Abstract][Full Text] [Related]
19. 3'-Deoxy-3'- Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456 [TBL] [Abstract][Full Text] [Related]
20. The clinical value of PERCIST to predict tumour response and prognosis of patients with oesophageal cancer treated by neoadjuvant chemoradiotherapy. Nakajo M; Kitajima K; Kaida H; Morita T; Minamimoto R; Ishibashi M; Yoshiura T Clin Radiol; 2020 Jan; 75(1):79.e9-79.e18. PubMed ID: 31662200 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]